Skip to main content
. Author manuscript; available in PMC: 2011 Jan 3.
Published in final edited form as: Bipolar Disord. 2010 Sep;12(6):593–605. doi: 10.1111/j.1399-5618.2010.00850.x

Table 3.

Common Treatment- Emergent Adverse Events (N=65)

Variable Frequency (%)
Risperidone (n=32) Divalproex Sodium (n=33)
Increased appetite 8 (25.0%) 10 (31.3%)
Irritable/agitated 0 (0.0%) 7 (21.9%) *
Stomach discomfort 6 (18.8%) 5 (15.6%)
Sleepiness 5 (15.6%) 4 (12.5%)
Fatigue/tiredness 5 (15.6%) 4 (12.5%)
Insomnia 0 (0%) 4 (12.5%)
Weight gain 3 (9.4%) 4 (12.5%)
*

p < .05 for comparison of Divalproex vs. Risperidone